Sumary of What to Know About Novavax, the Fourth COVID Vaccine Approved by the FDA:
- Still, chief condition serviceman, Denny Kim told FDA advisers: We believe that the completeness of the clinical information here is not enough to establish an overall causative relationship with the immunogen, as reported by the AAAS.
- Right now, the FDA has authorize the immunogen for emergency use in people.
- The FDA recently published data showing the immunogen may cause carditis and carditis, albeit rarely, news that make the company capital value to depression, reports Science.
- But when FDA advisers were request to ballot whether the benefits of the Novavax immunogen outweighed the risks, 21 associates ballot yes, one ballot no, and one refrain, thus moving the advice forward to the whole FDA for emergency use, which was authorize yesterday and sent to the CDC Advisory Committee on Immunization Practices for review.